Iclaprim: a differentiated option for the treatment of skin and skin structure infections

References

• WHO. Antimicrobial resistance global report on surveillance. World Health Organization 2014. [cited 2018 Aug 1] Available from: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf
   Google Scholar
• U.S. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States 2013. [cited 2018 Sep 23] Available from: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
   Google Scholar
• Golkar Z, Bagazra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. J Infect Dev Ctries 2014;8:129–136.
   PubMed Web of Science ®Google Scholar
• Ventola CL. The antibiotic resistance crisis, part 1: causes and threats. Pharm Therap 2015;40:277–283.
   Google Scholar
• Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: causes, consequences, and management. Front Public Health 2014;2:145.
   PubMedGoogle Scholar
• U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment. 2013. [cited 2018 Sep 23] Website: https://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf.
   Google Scholar
• Pulido-Cejudo A, Guzmán-Gutierrez M, Jalife-Montaño A, et al. Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Ther Adv Infect Dis 2017;4:143–161.
   PubMed Web of Science ®Google Scholar
• Patel N, Huang DB, Lodise TP. Potential cost savings opportunities with targeted use of iclaprim compared to vancomycin (VAN) among hospitalized patients with acute bacterial skin and skin structure infections due to potential avoidance of VAN-associated acute kidney injury (V-A AKI). Presented at: The 28th Annual European Congress of Clinical Microbiology and Infectious Diseases Meeting; April 21–24, 2018; Madrid, Spain; Poster P0283.
   Google Scholar
• Hawser S, Lociuro S, Islam K. In vitro spectrum of activity of iclaprim against various Gram-positive and Gram-negative pathogens. Presented at: The third international symposium on resistant Gram-positive infections; October 9–11, 2006, Niagara-on-the-Lake, Ontario, Canada; Poster CPLA 32.
   Google Scholar
• Kemnic TR, Coleman M. Trimethoprim sulfamethoxazole. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018. https://www.ncbi.nlm.nih.gov/books/NBK513232/.
   Google Scholar
• Oefner C, Bandera M, Haldimann A, et al. Increased hydrophobic interactions of iclaprim with S. aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J Antimicrob Chemother 2009;63:687–698.
   PubMed Web of Science ®Google Scholar
• Huang DB, Strader CD, MacDonald JS, et al. An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by Gram-positive including multidrug resistant bacteria. Open Forum Infect Dis. 2018 forthcoming.
   Web of Science ®Google Scholar
• Brandt R, Matthews A, Hall M, et al. Interactions of iclaprim with human cytochrome P450 enzymes. Presented at: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting; September 17–20, 2007; Chicago, IL; Poster A–807.
   Google Scholar
• Brandt R, John BA, Henderson SJ, et al. Absorption, pharmacokinetics, metabolism and excretion of iclaprim in healthy humans. Presented at: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting; September 17–20, 2007; Chicago, IL; Poster A–805.
   Google Scholar
• Park JH, Craig W, Marchillo K, et al. Identification of the in vivo pharmacokinetics and pharmacodynamic drivers of iclaprim. Antimicrob Agents Chemother. 2018 forthcoming; 62.
   Web of Science ®Google Scholar
• Morgan A, Cofer C, Stevens DL. Iclaprim, a novel DHFR inhibitor for skin and soft tissue infections. Future Microbiol 2009;4:131–143.
   PubMed Web of Science ®Google Scholar
• Hawser S, Weiss L, Fischer M, et al. AR-100, a novel diaminopyrimidine compound: bactericidal activity and post-antibiotic effect on Gram-positive pathogens. Presented at: The 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting; September 27–30, 2002; San Diego, CA; Poster F-2029.
   Google Scholar
• Hadváry P, de la Motte S, Klinger J, et al. Pharmacokinetics of iclaprim in subjects with varying degree of hepatic or renal insufficiency or obesity. Presented at: The 45th Annual Meeting of the Infectious Diseases Society of America; October 4–7, 2007; San Diego, CA; Poster 448.
   Google Scholar
• Sader HS, Fritsche TR, Jones RN. Potency and bactericidal activity of iclaprim against recent clinical Gram-positive isolates. Antimicrob Agents Chemother 2009;53:2171–2175.
   PubMed Web of Science ®Google Scholar
• Huang DB, File TM Jr., Dryden M, et al. Surveillance of iclaprim activity: in vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe. Diagn Microbiol Infect Dis 2018;90:329–334.
   PubMed Web of Science ®Google Scholar
• Huang DB, Hawser S, Gemmell CG, et al. In vitro activity of iclaprim against methicillin-resistant Staphylococcus aureus nonsusceptible to daptomycin, linezolid or vancomycin: a pilot study. Can J Infect Dis Med Microbiol 2017; 2017:3948626.
   PubMedGoogle Scholar
• Krievins D, Brandt R, Hawser S, et al. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob Agents Chemother 2009;53:2834–2840.
   PubMed Web of Science ®Google Scholar
• Stevens D, Leighton A, Dankner WM, et al. Efficacy of iclaprim in complicated skin and skin structure infections: preliminary results of ASSIST-1. Presented at: The 45th Annual Meeting of the Infectious Diseases Society of America; San Diego, CA (2007); Poster 1079.
   Google Scholar
• Dryden M, O’Hare MD, Sidarous E, et al. Clinical efficacy of iclaprim in complicated skin and skin structure infection (cSSSI): preliminary results from the ASSIST-2 clinical trial. Presented at: The 18th Annual European Congress of Clinical Microbiology and Infectious Diseases Meeting; April 19–22, 2008; Barcelona, Spain (2008).
   Google Scholar
• Hadváry P, Dankner W, Leighton A, et al. Iclaprim effect on the QT interval: results of combined ASSIST Phase III studies. Presented at: The 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/The 46th Infectious Diseases Society of America Annual Meeting; Washington, DC (2008); Poster L–1513.
   Google Scholar
• Lodise T, Bosso J, Kelly C, et al. Use of pharmacokinetic and pharmacodynamic analyses to determine the optimal fixed dosing regimen of iclaprim for treatment of serious Gram-positive infections. Antimicrob Agents Chemother Apr 2018;62:1–9.
   Web of Science ®Google Scholar
• Huang DB, O’Riordan W, Overcash JS, et al. A phase 3, randomized, double-blind, multicenter study to EValuate the safety and efficacy of intravenous Iclaprim versus vancomycin for the trEatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens: REVIVE-1. Clin Infect Dis 2018;66:1222–1229.
   PubMed Web of Science ®Google Scholar
• Holland TL, O’Riordan WO, McManus A, et al. A phase 3, randomized, double-blind, multicenter study to EValuate the safety and efficacy of intravenous Iclaprim versus Vancomycin for the trEatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens: REVIVE-2. Antimicrob Agents Chemother May 2018;62:1–10.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59(2):147–159.
   PubMed Web of Science ®Google Scholar
• Huang DB, Corey GR, Holland TL, et al. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents 2018. Epub ahead of print.
   Web of Science ®Google Scholar
• Ho JMW, Juurlink DN. Considerations when prescribing trimethoprim–sulfamethoxazole. Cmaj 2011;183:1851–1858.
   PubMed Web of Science ®Google Scholar
• Huang DB, Magnet S, Lemos B, et al. Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin and skin structure pathogens collected during 2004–2016. Presented at: The 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance; September 4–7, 2018; Lisbon, Portual Poster 60.
   Google Scholar
• Bryant AE, Katahira E, Huang DB, et al. Effects of iclaprim and trimethoprim on exotoxin production by methicillin-resistant Staphylococcus aureus. Presented at: IDWeek. 2017; Poster 1219.
   Google Scholar
• Stach CS, Herrera A, Schlievert PM. Staphylococcal superantigens interact with multiple host receptors to cause serious diseases. Immunol Res 2014;59:177–181.
   PubMed Web of Science ®Google Scholar
• Sangiovanni R, Stornelli N, Amin R, et al. Frequency of vancomycin-associated acute kidney injury and healthcare utilization among Veterans’ affairs patients with skin and skin structure infections. Presented at: The 28th Annual European Congress of Clinical Microbiology and Infectious Diseases Meeting; April 21–24, 2018; Madrid, Spain; Poster E0283.
   Google Scholar
• Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect 2012;65:128–134.
   PubMed Web of Science ®Google Scholar